Clinical Study Of Postoperative Adjuvant Chemotherapy With Modified FOLFOX₇ Regimen For Advanced Gastric Cancer

To evaluate the toxicity and efficacy of combination regimen with modified FOLFOX7 regimen as postoperative adjuvant chemotherapy for advanced gastric cancer.Methods104 gastric cancer patients, seventy-six were male and twenty-eight were female. Age was 29-78 years old, with a median age of 58±9.54 years. Chemotherapy regimen: intravenous infusion of oxaliplatin 130 mg/m2 for 2h on day 1, intravenous infusion of leucovorin 200 mg/m2 for 2h on day 1, and continuous infusion of 5-FU 2400 mg/m2 for 46h on day 1; and this regimen was repeated every 14-21 days. The effect and adverse reactions were recorded.ResultsThe median disease free survival time and overall survival time were 21.0 months and 23.5 months respectively. Leukopenia, gastrointestinal reactions and peripheral nerve toxicity of a ratio were greater than 30%, but most of them wereⅠ-Ⅱdegree of toxicity. No serious chemotherapy-related adverse reactions and no one cases of chemotherapy-related death occurred.Conclusions The postoperative adjuvant chemotherapy of modified FOLFOX7 regimen has expectable efficacy in treatment of advanced gastric cancer with light and well tolerable toxicity.